Immunovant Stock Today

IMVT -  USA Stock  

USD 8.23  0.24  2.83%

Immunovant is selling for under 8.23 as of the 22nd of October 2021; that is -2.83 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 8.0. Immunovant has more than 62 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Immunovant are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of September 2021 and ending today, the 22nd of October 2021. Please note, there could be an existing legal relationship between Immunovant (IMVT) and Immunovant (HSAC). Click here to learn more.
 Market Performance
0 of 100
  Odds Of Distress
Over 62
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company has 97.97 M outstanding shares of which 4.28 M shares are currently shorted by private and institutional investors with about 5.41 trading days to cover. More on Immunovant

Immunovant Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Immunovant's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Immunovant or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Immunovant generated a negative expected return over the last 90 days
Immunovant has high historical volatility and very poor performance
Immunovant has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (111.19 M).
Immunovant currently holds about 379 M in cash with (90.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.3.
Immunovant has a frail financial position based on the latest SEC disclosures
Roughly 65.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Barnett Eva Renee of 333000 shares of Immunovant subject to Rule 16b-3
Immunovant Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Immunovant SEC Filings
Immunovant SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameImmunovant
Related EntityHSAC (Immunovant)
Average Analyst Recommendation
Analysts covering Immunovant report their recommendations after researching Immunovant's financial statements, talking to executives and customers, or listening in on Immunovant's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Immunovant. The Immunovant consensus assessment is calculated by taking the average forecast from all of the analysts covering Immunovant.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Immunovant based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Immunovant financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares75.7 M87.8 M
Fairly Down
Slightly volatile
Weighted Average Shares Diluted75.7 M87.8 M
Fairly Down
Slightly volatile
Total Assets445.1 M412.5 M
Significantly Up
Slightly volatile
Total Liabilities19.3 M21 M
Significantly Down
Slightly volatile
Current Assets441.3 M409 M
Significantly Up
Slightly volatile
Current Liabilities17.7 M18.8 M
Notably Down
Slightly volatile
Total Debt3.1 M3.1 M
Slightly Down
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Immunovant's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Immunovant's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Immunovant's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immunovant's financial leverage. It provides some insight into what part of Immunovant's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Immunovant's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Immunovant deploys its capital and how much of that capital is borrowed.
Immunovant cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 3.06 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Immunovant has a current ratio of 18.38, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(89.91 Million)Share
Immunovant (IMVT) is traded on NASDAQ Exchange in USA. It is located in 320 West 37th Street and employs 68 people. Immunovant is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 854.31 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunovant's market, we take the total number of its shares issued and multiply it by Immunovant's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Immunovant conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 97.97 M outstanding shares of which 4.28 M shares are currently shorted by private and institutional investors with about 5.41 trading days to cover. Immunovant currently holds about 379 M in cash with (90.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.3.
Check Immunovant Probability Of Bankruptcy
Immunovant has a total of ninety-seven million nine hundred seventy thousand outstanding shares. Immunovant retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company outstanding shares. 65.13 (percent) of Immunovant outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how much assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Immunovant Ownership Details

Immunovant Stock Price Odds Analysis

What are Immunovant's target price odds to finish over the current price? Attributed to a normal probability distribution, the odds of Immunovant jumping above the current price in 90 days from now is about 72.99%. The Immunovant probability density function shows the probability of Immunovant stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Immunovant has a beta of 0.5464. This usually indicates as returns on the market go up, Immunovant average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Immunovant will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Immunovant is significantly underperforming DOW.
 Odds Down 8.23HorizonTargetOdds Up 8.23 
26.88%90 days
Based on a normal probability distribution, the odds of Immunovant to move above the current price in 90 days from now is about 72.99 (This Immunovant probability density function shows the probability of Immunovant Stock to fall within a particular range of prices over 90 days) .

Immunovant Historical Income Statement

Immunovant Income Statement is one of the three primary financial statements used for reporting Immunovant's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Immunovant revenue and expense. Immunovant Income Statement primarily focuses on the company's revenues and expenses during a particular period.
View More Fundamentals

Immunovant Stock Against Markets

Picking the right benchmark for Immunovant stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Immunovant stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Immunovant is critical whether you are bullish or bearish towards Immunovant at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immunovant without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Suggestion Now


Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
All  Next Launch Module
Please see Risk vs Return Analysis. Note that the Immunovant information on this page should be used as a complementary analysis to other Immunovant's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Immunovant Stock analysis

When running Immunovant price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
The market value of Immunovant is measured differently than its book value, which is the value of Immunovant that is recorded on the company's balance sheet. Investors also form their own opinion of Immunovant's value that differs from its market value or its book value, called intrinsic value, which is Immunovant's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunovant's market value can be influenced by many factors that don't directly affect Immunovant underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunovant's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunovant value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunovant's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.